# Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases

> **NCT04711824** · PHASE1,PHASE2 · RECRUITING · sponsor: **Colette Shen** · enrollment: 41 (estimated)

## Conditions studied

- Breast Cancer
- Brain Metastases, Adult

## Interventions

- **DRUG:** Olaparib
- **RADIATION:** Stereotactic Radiosurgery
- **DRUG:** Durvalumab
- **DRUG:** Physicians Choice systemic chemotherapy

## Key facts

- **NCT ID:** NCT04711824
- **Lead sponsor:** Colette Shen
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-09
- **Primary completion:** 2026-02
- **Final completion:** 2026-11
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2025-12-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04711824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04711824, "Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04711824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*